The Impact of Biopharma 4.0 on Bioprocessing
Explore the expected impacts of Biopharma 4.0 on the industry through technologies like artificial intelligence, automation, and digital transformation.
What is Biopharma 4.0?
Biopharma 4.0 is the comprehensive application of Industry 4.0 principles and advanced digital technologies, such as artificial intelligence, across bioprocessing operations. Industry 4.0 refers to the digital transformation happening across multiple manufacturing industries, and is often also called the Fourth Industrial Revolution.
While the Fourth Industrial Revolution emerged in Germany around 2011, concepts specific to Pharma 4.0 began to solidify later. It gained significant formal exploration in 2017 with the introduction of the whitepaper titled “Pharma 4.0: A Roadmap for Digital Pharmaceutical Manufacturing.” The International Society for Pharmaceutical Engineering (ISPE) subsequently trademarked the term Pharma 4.0 in the same year.
As advanced technologies become increasingly commonplace, the need to integrate Biopharma 4.0 technologies into organizational processes is becoming increasingly evident. In the article below, we explore how Biopharma 4.0 can help improve product quality, increased productivity, speed, and regulatory compliance.
Exploring the Core Pillars of Biopharma 4.0
Artificial Intelligence and Machine Learning
With applications from research and development to large-scale data analysis, artificial intelligence (AI) and machine learning (ML) have been at the forefront of advancement across all industries.
This trend is exemplified by major biopharma companies looking to acquire promising startups. One example of this is Sanofi’s acquisition, completed in 2022, of immuno-oncology Amunix Pharmaceuticals, a company leveraging AI in its proprietary technology platform, which is highly complementary to Sanofi’s existing R&D platforms.
According to Transparency Market Research Inc., the value of AI in pharma is anticipated to be at $13.1 billion by 2034, which is a CAGR of 18.8% from 2024. More in-depth details and definitions are explored in our previous article, “The Effect of Artificial Intelligence on Biopharma”.
Process Automation Systems
Throughout any biopharmaceutical operation, there can be a variety of routine and repetitive tasks that consistently consume valuable time and resources. From laboratory procedures to manufacturing workflows and administrative functions, these manual steps can be prone to human error, bottlenecks, and inefficiencies.
To combat this, sophisticated process automation systems have been developed, enabling these often tedious, repetitive tasks to be completed automatically by machines or software. For instance, in research and development, automation can manage high-throughput screening, liquid handling, and data logging, accelerating discovery pipelines.
By offloading these time-consuming, repetitive operations to automated solutions, biopharma organizations empower their employees to dedicate their expertise where it truly matters — to complex problem-solving, critical decision-making, and innovation.
Data-Driven Supply Chain Management
In order to optimize operations and enhance visibility, incorporating data-driven decision-making tools for supply chains has become critical. With the wealth of information available, it is crucial to incorporate tools that effectively decode and utilize this data.
Some of the ways technology is commonly used in data-driven decision-making include predictive analysis and inventory optimization. More detailed information on data-driven decision making is available in our article “Data-Driven Decisions for Biopharma Supply Chains”.
Digital Transformation and Connectivity
Although it comes with its fair share of cybersecurity concerns, finding new ways to effectively relay information across teams has become critical to speeding up operations and keeping everyone across organizations well-informed.
At its core, digital transformations in Biopharma 4.0 aim to break down traditional silos, integrate disparate systems, and create a seamless flow of information across the drug lifecycle, from early-stage research to patient engagement. In a Biopharma 4.0 environment, individual sensors, instruments, and software platforms are linked to form a data exchange network.
To be utilized effectively, the vast amount of data collected requires robust storage solutions. This is where cloud software comes in. Instead of relying solely on in-house data centers with limited storage capabilities and scalability, biopharma companies are increasingly leveraging cloud platforms. Some commonly encountered cloud software in biopharma include Microsoft Azure, Google Cloud Platform, IBM Cloud, and Amazon Web Services.
Expected Impacts on the Value Chain
The implementation of the technologies listed above, as well as many others, is expected to have profound impacts throughout the industry. Affected areas across the value chain include research and development, process development and scale-up, manufacturing and production, quality control and compliance, and supply chain logistics.
As mentioned in the section above defining Biopharma 4.0, implementing the technologies of the Fourth Industrial Revolution is expected to reduce operator error, speed up production, accelerate drug discovery, optimize resource allocation, and more. To stay ahead in the competitive biopharma and bioprocessing landscape, early adoption of these process-altering technologies is critical.
Challenges and Considerations
One of the biggest challenges facing the industry as we adopt these new technologies is finding staff with the skills and expertise required to operate them. According to BioProcess International, there is currently a large gap between the current talent pool and the skills required to thrive in a Biopharma 4.0 environment.
To combat this gap, companies could consider creating and implementing more rigorous training programs. However, developing such training programs is a challenge in itself, as it requires subject matter experts and incurs significant costs related to development time and delivery.
Beyond training development, cost is one of the biggest challenges facing companies looking to adopt the Biopharma 4.0 principles. Whenever a new technology is implemented into a process, there is an associated cost. Given the volume of specialized software and equipment available across various areas of the value chain, even partial adoption can come with a substantial investment.
Lastly, as technologies like AI are rapidly evolving, it is difficult for regulatory bodies to keep pace with their regulation. This means it is important for quality professionals to pay close attention to announcements from regulatory bodies like the FDA for changes in compliance parameters for these technologies. Find more information on regulatory bodies and biopharma regulations in our article “Understanding the Evolving Biopharma Regulatory Landscape”.
Future Outlook Beyond Biopharma 4.0
Although Biopharma 4.0 is a crucial topic for organizations, the breadth of available technologies suggests that full industry-wide adoption will likely take years. Many experts, including those at ISPE, anticipate that developments in AI will have a significant and long-term impact on the industry and society as a whole.
Additionally, continuous research into these technologies means organizations must be able to adapt as advancements are made and recruit staff capable of grasping detailed changes to complex technologies.
Due to the long adaptation time of Biopharma 4.0, many experts are currently focused on the immediate implications and adjustments of technologies like AI, rather than speculating extensively about a distant future. However, this Fourth Industrial Revolution has made it clear that companies need to change their processes to be more flexible and able to quickly adapt as technology improves.
Stay Ahead of Biopharma Industry Changes with HPNE
In this rapidly evolving industry, it is important to work with reliable partners and distributors. At HPNE, a Getinge Company, we have dedicated ourselves to combining decades of bioprocess experience with an extensive, top-of-the-line product portfolio, and world-class customer service.
Our Product Managers and Customer Service teams are readily available and look forward to working with you to address your bioprocess challenges. Learn what bioprocessing equipment is right for your unique needs, or learn how we can provide custom solutions by reaching out to our team at info@hp-ne.com, or through our contact us page.
Share article
About HPNE
As the industry needs grow, High Purity New England, Inc. continues to supply the biopharmaceutical industry with a range of innovative products, from drug discovery and development to fill-finish, including their flagship product, custom single-use assemblies, as well as pumps, sensors, bioreactor systems, storage and handling solutions and other single-use solutions. Along with their own manufactured products for the global market, they are also a distributor for more than 18 brands in North America.
